Ken Griffin Galapagos Nv Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Galapagos Nv stock. As of the latest transaction made, Citadel Advisors LLC holds 15,969 shares of GLPG stock, worth $499,670. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,969

Previous 40,400 60.47%

Holding current value

$499,670

Previous $1.13 Million 51.06%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$27.87 - $34.64 $118,781 - $147,635	4,262 Added 36.41%	15,969 $553,000
Q2 2025 Aug 14, 2025	BUY	$23.04 - $29.2 $269,729 - $341,844	11,707 New	11,707 $327,000
Q4 2024 Feb 14, 2025	SELL	$25.22 - $31.05 $216,917 - $267,061	-8,601 Reduced 14.84%	49,373 $1.36 Million
Q3 2024 Nov 14, 2024	SELL	$24.2 - $30.67 $2.32 Million - $2.94 Million	-95,962 Reduced 62.34%	57,974 $1.67 Million
Q2 2024 Aug 14, 2024	BUY	$24.78 - $32.48 $3.28 Million - $4.3 Million	132,439 Added 616.08%	153,936 $3.81 Million

Q1 2024 May 15, 2024	SELL	$32.2 - $42.44 $7.76 Million - $10.2 Million	-240,887 Reduced 91.81%	21,497 $692,000
Q4 2023 Feb 14, 2024	SELL	$31.87 - $40.71 $6.61 Million - $8.45 Million	-207,484 Reduced 44.16%	262,384 $10.7 Million
Q3 2023 Nov 14, 2023	BUY	$34.17 - $42.98 $8.08 Million - $10.2 Million	236,577 Added 101.41%	469,868 $16.2 Million
Q2 2023 Aug 14, 2023	SELL	$37.4 - $44.52 $8.22 Million - $9.79 Million	-219,827 Reduced 48.51%	233,291 $9.49 Million
Q1 2023 May 15, 2023	BUY	$36.5 - $48.0 $4.3 Million - $5.65 Million	117,687 Added 35.09%	453,118 $17.5 Million
Q4 2022 Feb 14, 2023	BUY	$37.44 - $46.51 $548,795 - $681,743	14,658 Added 4.57%	335,431 $14.9 Million
Q3 2022 Nov 14, 2022	BUY	$42.27 - $57.6 $68,435 - $93,254	1,619 Added 0.51%	320,773 $13.7 Million
Q2 2022 Aug 15, 2022	BUY	$52.3 - $71.59 $13.3 Million - $18.2 Million	254,162 Added 391.07%	319,154 $17.8 Million
Q1 2022 May 16, 2022	SELL	$51.32 - $68.5 $23.4 Million - $31.2 Million	-455,196 Reduced 87.51%	64,992 $4.03 Million
Q4 2021 Feb 14, 2022	BUY	$47.03 - $57.12 $939,189 - $1.14 Million	19,970 Added 3.99%	520,188 $28.7 Million
Q3 2021 Nov 15, 2021	BUY	$52.17 - $70.2 $2.45 Million - $3.3 Million	47,039 Added 10.38%	500,218 $26.3 Million
Q2 2021 Aug 16, 2021	BUY	$68.86 - $83.34 $11.1 Million - $13.5 Million	161,512 Added 55.38%	453,179 $31.2 Million
Q1 2021 May 17, 2021	BUY	$76.15 - $111.94 $18.4 Million - $27 Million	241,449 Added 480.8%	291,667 $22.5 Million
Q4 2020 Feb 16, 2021	SELL	$96.85 - $148.25 $3.43 Million - $5.26 Million	-35,450 Reduced 41.38%	50,218 $4.97 Million
Q3 2020 Nov 16, 2020	BUY	$122.47 - $213.56 $6.98 Million - $12.2 Million	57,032 Added 199.16%	85,668 $12.2 Million
Q2 2020 Aug 14, 2020	BUY	$185.52 - $231.25 $505,542 - $630,156	2,725 Added 10.52%	28,636 $5.65 Million
Q1 2020 May 15, 2020	SELL	$143.0 - $274.03 $310,739 - $595,467	-2,173 Reduced 7.74%	25,911 $5.08 Million
Q4 2019 Feb 14, 2020	BUY	$146.12 - $215.82 $1.02 Million - $1.5 Million	6,957 Added 32.93%	28,084 $5.81 Million
Q3 2019 Nov 14, 2019	SELL	$130.44 - $187.64 $1.36 Million - $1.95 Million	-10,389 Reduced 32.96%	21,127 $3.23 Million
Q1 2019 May 15, 2019	BUY	$89.61 - $117.78 $1.52 Million - $2 Million	16,952 Added 116.4%	31,516 $0
Q4 2018 Feb 14, 2019	BUY	$87.81 - $110.65 $965,734 - $1.22 Million	10,998 Added 308.41%	14,564 $1.34 Million
Q1 2018 May 11, 2018	BUY	$94.51 - $120.23 $65,778 - $83,680	696 Added 24.25%	3,566 $356,000
Q4 2017 Feb 09, 2018	SELL	$84.48 - $104.02 $955,384 - $1.18 Million	-11,309 Reduced 79.76%	2,870 $269,000
Q3 2017 Nov 09, 2017	BUY	$73.17 - $103.47 $1.04 Million - $1.47 Million	14,179	14,179 $1.44 Million

Others Institutions Holding GLPG

# of Institutions

100

Shares Held

15.3M

Call Options Held

64.6K

Put Options Held

39.6K

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $2.06B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account